Information Provided By: 
Fly News Breaks for February 9, 2017
ACOR
Feb 9, 2017 | 08:22 EDT
Leerink analyst Paul Matteis notes that Acorda Therapeutics' positive Phase 3 data of CVT-301 showing a statistically significant improvement in motor function in patients with Parkinson's disease was mostly expected. While the analyst says the data is "solid," he points out that it was not "as pristine" as Phase 2. He reiterates a Market Perform on the shares.
News For ACOR From the Last 2 Days
There are no results for your query ACOR
